Top 20 blockbuster drugs in the late-stage pipeline — EvaluatePharma
Every time news hits about another biosimilar to Humira, analysts are reminded that AbbVie $ABBV is living on borrowed time. Ever since the big split with Abbott, the company has been wheeling and dealing its way into Phase III in a huge gamble that it can hold off copycats long enough to field a slate of drugs capable of replacing a therapy that now delivers $16 billion a year.
The new list from EvaluatePharma on the top 20 late-stage drugs in the pipeline — included in its big annual report on the industry — underscores just how hard that is, and also how much progress AbbVie is making.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.